Nivolumab is an immunotherapy drug that has been described as a potential "game-changer" in cancer as presented at the European Cancer Congress. Researchers found out that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.
An immunotherapy drug recently-approved for a blood cancer called multiple myeloma can help produce even better results if it is administered during the early stages of the disease. These are the findings of a new study conducted by a team of researchers from the University of Torino in Italy.
09 Aug '24 16:35PM
